




UMC Utrecht



Low gradient CoA in the adult: what to treat ?



Michiel Voskuil, MD, PhD
Dept Cardiology
Associate Professor

In memoriam

Marc Buijsrogge

Thoracic surgeon

48y

Heart & lung transplantation

Mechanical assist devices

Minimal invasive surgery

Trainer of residents



Why do a CoA intervention in an adult?

➤ **Hypertension!**


CoA – Hypertension

- Hypertension in $\frac{2}{3}$ rd of adult patients after successful CoA repair
- Untreated, average survival is 35 years; 75% died <50 yrs: heart failure, coronary artery disease, aortic dissection
- Causes hypertension:
 - re-CoA
 - baroreceptor dysfunction
 - increased arterial stiffness
 - elevated sympathetic nerve activity / increased RAS activation
 - Aortic arch hypoplasia / gothic arch #
 - Stenting safe / efficient? *

Stenting of CoA – effects on BP


Medium-term systemic blood pressure after stenting of aortic coarctation: a systematic review and meta-analysis

Timion A Meijs,¹ Evangeline G Warmerdam,¹ Martijn G Slieker,² Gregor J Krings,² Mirella M C Molenschot,² Folkert J Meijboom,¹ Gertjan T Sieswerda,¹ Pieter A Doevendans,^{1,3} Berto J Bouma,⁴ Robbert J de Winter,⁴ Barbara J M Mulder,⁴ Michiel Voskuil¹



Effects of treatment of HT – clinical outcome

Associations of reduction in blood pressure with risk reduction for total major cardiovascular events for adults aged <65 and ≥65



Stenting of CoA – effects on clinical outcome??

- National registry of adult congenital patients in Netherlands
 - 1035 patients from this CONCOR database
 - Mean FU 30.3y; mean age 36.9y
 - Cardiovascular events (myocardial infarction, aneurysm, dissection, TIA/stroke, heart failure, death): **213/753 (28%)**
-
- Predictors events?
 - Blood pressure?
 - Effects interventions?

Stenting in mild CoA – efficacious?

Stenting mild CoA?

Case

- Male, 38y
- Coarctation aortae
- Bicuspid valve
- Hypertension
- 2001: stent implantation (15mm)


- 2017: hypertension borderline controlled; 2 antihypertensives
- MR: non-conclusive

➤ Cath



Stenting mild CoA?

3DRA





Stenting mild CoA?

Pressures

- Anesthesia:
 - No gradient under BP 100/60 mmHg
- After 50ug ephedrine: no gradient
- RA pacing 120/min => gradient 15-20 mmHg
- After adrenaline 30ug (BP 180mmHg systolic):
 - gradient 35 mmHg


Stenting mild CoA?

Intervention



Stenting mild CoA?


Intervention



BeGraft Aortic 24x48mm

Stenting mild CoA?

Outcome



- <5 mmHg gradient after stenting
- Follow-up: 24h ABPM: 125/74, nice nocturnal dip (ramipril 10mg)


Stenting mild CoA?

Case II

- Male 26y
 - Medical history
 - 1989: coarctectomy patch angioplasty (Goretex)
 - 1989: Surgical closure perimembranous VSD (Goretex)
 - 2011: Exercise test: hypertensive; TTE en MR no Re-CoA
 - 2012: Suspicion re-CoA: gradient 15mmHg -> conservative
 - 2015: hypertension
- Re-cath


Stenting mild CoA?

Case II



Stenting mild CoA?

Case II



- 0 mmHg gradient after stenting
- Follow-up: 24h ABPM: 120/68, nice nocturnal dip (no medication)

Case III

- Male, 37 years of age
- TGA with VSD and CoA
- History:
 - 1980: correction CoA (patch angioplasty); banding PA
 - 1982: arterial switch with closure VSD, removal banding PA and patch plasty RVOT
 - 2012: gradient aortic arch 30mmHg – balloon interrogation; considered too complex for stenting
 - 2013: hypertension; multiple antihypertensives
(3 types in 2017)

3DRA pre



Gradient 15mmHg; after adrenaline 50ug: 60 mmHg
(BP 180 mmHg systolic)


Balloon interrogation



Stent implantation





No 1



No 2

Stent implantation




End result

Pressure measurement after stenting:

Gradient 0 mmHg at BP 145 mmHg systolic

→ *Follow-up: normotensive; all medication stopped*



Angio



3DRA

Stenting mild CoA?

2018 AHA/ACC Guidelines Adults With Congenital Heart Disease

Therapeutic

I	B-NR	6. Surgical repair or catheter-based stenting is recommended for adults with hypertension and significant native or recurrent coarctation of the aorta. ^{S4.2.6-1,S4.2.6-2,S4.2.6-8-S4.2.6-12}
I	C-EO	7. GDMT is recommended for treatment of hypertension in patients with coarctation of the aorta. ^{S4.2.6-13}
IIb	B-NR	8. Balloon angioplasty for adults with native and recurrent coarctation of the aorta may be considered if stent placement is not feasible and surgical intervention is not an option. ^{S4.2.6-14}

Stenting mild CoA?

2018 AHA/ACC Guidelines Adults With Congenital Heart Disease

- Significant native or recurrent aortic coarctation has been defined as follows:
 - upper extremity / lower extremity resting peak-to-peak gradient >20 mm Hg or mean Doppler systolic gradient >20 mm Hg
 - upper extremity / lower extremity gradient >10 mm Hg or mean Doppler gradient >10 mm Hg plus either decreased LV systolic function or AR
 - upper extremity / lower extremity gradient >10 mm Hg or mean Doppler gradient >10 mm Hg with collateral flow
 - This should be coupled with anatomic evidence for CoA, typically defined by advanced imaging (CMR, CTA)
 - Presence systemic hypertension!


Stenting mild CoA?

2018 AHA/ACC Guidelines Adults With Congenital Heart Disease

- Systemic hypertension **may not consistently be identifiable at rest**; therefore, ambulatory blood pressure monitoring can be useful in identifying and appropriately managing patients with ambulatory hypertension
- Why not measure gradients with 'exercise' at the cathlab?!

Stenting mild CoA?

- Retrospective study in 50 CoA patients >50kg with a peak systolic gradient (PSG) ≤ 20 mmHg during cardiac catheterization
- Subsequent interventional management (stenting or balloon dilatation), complications, and medium-term clinical outcome were assessed.



Stenting mild CoA?

Table 1. Baseline characteristics and invasive measurements during cardiac catheterization.

	Overall n=50 n (%) or mean±SD	Epinephrine PSG >20 mmHg n=24 n (%) or mean±SD	Epinephrine PSG ≤20 mmHg n=26 n (%) or mean±SD	<i>p</i> -value*
Age at catheterization (years)	27.3±13.2	22.4±11.5	31.7±13.4	0.011
Female sex	18 (36)	7 (29)	11 (42)	0.39
BMI (kg/m ²)	23.1±3.8	22.7±4.2	23.4±3.6	0.49
Number of prior CoA interventions				0.93
0	9 (18)	4 (17)	5 (19)	
1	25 (50)	13 (54)	12 (46)	
≥2	16 (32)	7 (29)	11 (35)	
First CoA intervention				0.06
Surgery	25 (61)	9 (45)	16 (76)	
Stenting	9 (22)	5 (25)	4 (19)	
Balloon angioplasty	7 (17)	6 (30)	1 (5)	
Non-invasive systolic right arm- leg gradient (mmHg)	8±14	12±12	4±15	0.12

Stenting mild CoA?


Table 1. Baseline characteristics and invasive measurements during cardiac catheterization.

	Overall n=50 n (%) or mean±SD	Epinephrine PSG >20 mmHg n=24 n (%) or mean±SD	Epinephrine PSG ≤20 mmHg n=26 n (%) or mean±SD	<i>p</i> -value*
Office hypertension	34 (68)	16 (67)	18 (69)	1.0
Hypertension on 24-hour ABPM	29 (78)	15 (75)	14 (82)	0.70
Hypertensive response to exercise	18 (67)	11 (92)	7 (47)	0.019
Use of any AHM	18 (36)	9 (38)	9 (35)	1.0
Number of AHM	0.7±1.0	0.9±1.1	0.5±0.8	0.26
LV mass index (g/m ^{2.7})	38±14	36±17	39±11	0.58
LV hypertrophy	8 (21)	3 (15)	5 (26)	0.45

Discussion


- High incidence adverse events in CoA patients because of high incidence of hypertension
- Re-CoA treatable cause of hypertension
- Even a subgroup of mild CoA (and arch hypoplasia?) can be treated to improve outcome
 - More long-term robust follow-up is needed
 - Early detection of re-CoA crucial

Future



CFD

M Conijn



4D MRI

E Warmerdam

Thank you

WKZ

Gregor Krings
Mirella Molenschot
Heynric Grotenhuis
Hans Breur
Gabrielle van Iperen
Paul Schoof
Felix Haas
Bram van Wijk



AZU

Gert-Jan Sieswerda
Folkert Meijboom
Han Dronkert
Heleen van der Zwaan
PhD
Evangeline Warmerdam
Timion Meijs
Anouk Franken (student)